Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Conference 11.10.2023 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

October 12, 2023

Bariatric surgery reduces risk of MACE and death in patients with obstructive sleep apnea

Bariatric surgery, also called weight-loss or metabolic surgery, was associated with a 42% lower risk of major adverse cardiovascular events, including heart failure, heart attack,

June 27, 2023

Same-sex sexual behavior may be a common feature of primate reproduction, study suggests

Observations of a wild colony of macaques over three years show same-sex sexual behavior among males is widespread and may be beneficial.

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.